Lactococcus Lactis Oral Composition for Skin Bacterial Growth Control

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing treatments for skin conditions caused by abnormal bacterial growth, such as those from Staphylococcus aureus, are limited in effectiveness and often lead to antibiotic resistance, and direct application of lactic acid bacteria is impractical for whole-body prevention.

Innovation Solution

A composition containing Lactococcus lactis JCM5805 strain is orally administered to prevent or ameliorate skin conditions by suppressing abnormal bacterial growth through the augmentation of antibacterial genes in the skin.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If antibiotics are administered for bacterial skin infections, then the infection is treated, but antibiotic resistance emerges

Engineering Contradiction:
Improveinfection treatment effectivenessVSAvoidantibiotic resistance
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of antibiotics into a beneficial approach by using lactic acid bacteria that naturally produce antibacterial substances. Instead of relying on external antibiotic drugs that select for resistant bacteria, the invention uses probiotics that actively suppress pathogenic bacteria through their metabolic products, thereby treating infections while preventing resistance development

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent introduces lactic acid bacteria as an intermediary substance between the host and pathogenic bacteria. These bacteria colonize the skin and produce antibacterial compounds that indirectly neutralize pathogens without direct antibiotic intervention, thus avoiding the selection pressure that leads to resistance

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If lactic acid bacteria are directly applied onto the skin, then bacterial growth is inhibited, but it is impossible to always keep applying them on the whole body

Engineering Contradiction:
Improvebacterial growth inhibitionVSAvoidapplication convenience
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent transitions from topical application (surface level) to oral administration (internal level). By taking lactic acid bacteria through the mouth, they are transported via the gastrointestinal tract to the skin, where they colonize and provide protection. This dimensional shift from external to internal application makes whole-body coverage possible and convenient

Inventive Principle:
Principle #17Another dimension (Dimensionality change)

Solution Approach 2:

The patent enables the lactic acid bacteria to self-transport and self-colonize on the skin through oral intake. The bacteria naturally adhere to skin cells and establish residence without requiring external application, thereby providing continuous protection throughout the body automatically

Inventive Principle:
Principle #25Self-service

3Reliability

If existing antiviral drugs are used for viral infections, then limited viral species are treated, but treatment is nothing more than symptomatic therapy

Engineering Contradiction:
Improveviral infection treatmentVSAvoidtreatment applicability
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies a universal approach by using lactic acid bacteria that can inhibit multiple types of pathogenic bacteria through their antibacterial substances. This single probiotic strain provides broad-spectrum protection against various skin pathogens, making the treatment applicable to different infection types without requiring species-specific drugs

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Oral intake of Lactococcus lactis JCM5805 strain enhances skin resistance to pathogens like Staphylococcus aureus, reducing skin inflammation and pathological changes by increasing expression of antibacterial genes.

Implementation Method 1

lactic acid bacteria, such as Lactobacillus delbrueckii and Lactobacillus buchneri, bind to transient pathogenic skin bacteria and inhibit their growth

Methodology Applied
Scientific EffectAdhesion: Adhesive

Implementation Method 2

Lactococcus lactis JCM5805 strain enhances skin resistance to pathogens like Staphylococcus aureus, reducing skin inflammation and pathological changes by increasing expression of antibacterial genes

Methodology Applied
Scientific EffectAntibacterial activity:

Data Source

PatentEP3513799B1Composition which contains lactic acid bacterium as effective component and which is for preventing or ameliorating skin condition deterioration caused by abnormal proliferation of specific bacterium in skin
Publication Date: 2025.07.09 KIRIN HOLDINGS KK
  • EP3513799B1 patent drawingFigure 1
  • EP3513799B1 patent drawingFigure 2
  • EP3513799B1 patent drawingFigure 3

AI summary

Provided is a pharmaceutical composition and food composition for treating or preventing a skin disease caused by abnormal growth of a skin bacterium or infection with a pathogenic microorganism. A composition comprising a lactic acid bacterium as an active ingredient, for suppressing bacterial abnormal growth, or preventing or ameliorating deterioration of skin condition caused by a bacterial bnormal growth, by oral intake thereof.